Editorial

Doubling our precision of risk stratification in early prostate cancer – too good to be true?

Mark Emberton

Director - Division of Surgery and Interventional Science,

University College London,

London WC1E 6AU

m.emberton@ucl.ac.uk

It is difficult to over-estimate the enormity of the revolution involved in transitioning away from an organ-based system of care (prostatectomy or radiotherapy to prostate cancer of any grade, number, location or volume) to one in which the target condition is defined and verified, and then subsequently treated with a margin. Since Hugh Hampton-Young undertook the first radical prostatectomy over 100 years ago, an organ-based system of care has been the only plausible strategy for men with early prostate cancer. This is because our risk stratification methods could certainly tell us who had prostate cancer when it was indeed identified. But they could not tell us with any degree of precision how much cancer was present (number of foci and volume of cancer), what grade it was and where within the prostate the cancer resided. Surgery or radiotherapy to the whole gland, it was thought, was a reasonable mitigation (at the cost of over-treatment in a significant proportion of men) to the systematic under-estimation of risk to the patient. The degree to which our attempts at risk stratification failed our patients was
emphasized in a recent UK report that showed a greater than 50% increase in histological grade (the most important determinant of risk) at radical prostatectomy against the risk the patient was told at the time of diagnosis (1). ‘Up-grading’ is an inverse measure of the quality of our risk stratification.

With this background it should be of little surprise that there remains considerable skepticism about our ability to localize disease within the prostate, define it’s volume with some degree of precision and identify the worst histological grade within the tumour most of the time. These conditions, which most patients – quite reasonably - might expect of a modern cancer diagnostic programme, need to be fulfilled if we are to move away from an organ-based strategy for all towards a system of care that risk stratifies with precision, treats only those that are likely to benefit and tries to preserve tissue and function when we are able to do so.

The technologies and developments that have permitted a reduction in risk stratification error from 50% to around 5% are the subject of a paper in this issue (2). This group from Australia exploited a cohort of men that underwent a series of tests that culminated in a radical prostatectomy. These comprised: high quality multi-parametric MRI at a range of magnet strengths; formal scoring or the MRI using an ordinal scale of risk; a subsequent 5mm transperineal template guided biopsy modified from Winston Barzell’s original account; additional sampling of prostate sectors that corresponded to a high likelihood of clinically significant cancer based on the MRI reading - a process otherwise known as ‘targeting’. The outputs of these tests were compared to the presence or absence of clinically significant prostate
cancer in the 100 prostate lobes evaluated from the 50 eligible men that underwent surgery. The authors’ *a priori* threshold for declaring clinically significant disease in the tests was the presence or a PIRADS 4-5 MRI lesion (with or without concordant pathology) and/or the presence of exclusive Gleason pattern 3 amounting to 4mm or more maximum cancer core length or the presence of any Gleason pattern 4 or 5 (3). At radical prostatectomy slightly different criteria were employed. Clinically significant prostate cancer constituted an exclusive Gleason pattern 3 lesion provided it was ≥1.3cc. The presence of patterns 4 and 5 within the lesion triggered ‘significance’ as did evidence of capsular invasion or extra-prostatic extension.

Although a small study, the men were exposed to the best diagnostic profile that it was possible to have and were subjected to a reference test which most of us would trust.

What did they find? Just how well did a modern diagnostic panel rule in or rule out prostate cancer that exceeded a minimum threshold of 4mm of Gleason pattern 3?

Within the hundred lobes that were evaluated, 21 clinically significant cancers were identified in the diagnostic process. At radical prostatectomy two of these were at the midline and therefore attributed - within the rules - to both sides of the gland. In one of these cases there was a 5mm diameter (0.1cc) Gleason 3+4 lesion with 10% Gleason pattern 4 that was overlooked by the combined diagnostic process. A lesion of this volume can evade a well-applied sampling strategy based on a 5mm sampling frame, especially if the lesion is non-spherical. The relatively low component of pattern 4 combined with the relatively low volume means that MRI would also have a hard time detecting it. Under the conditions described in this paper the authors concluded that
combined MRI and intensive biopsy conferred a sensitivity of 97% and a negative predictive value of 91% for a fairly conservative definition of clinically significant disease. This level of accuracy, which is nearly twice as good as we were previously capable of, will result in major benefits for patients in terms of communicating risk with an order of precision that was hitherto not possible. This should translate to more appropriate treatment allocation - both avoiding unnecessary treatment and having treatment when it is likely to be beneficial. It should also result in a significant proportion of patients being offered the option of a tissue preserving therapy when it is an option (4). Most importantly, this new precision opens up an opportunity for greater involvement of the patient in the process of informed decision-making (5). Something that was not really possible in the face of yesterday’s diagnostic uncertainty.

References


that really promote shared decision making: the pace quickens. BMJ. 2015 Feb 10;350:g7624.

Acknowledgements

Mark Emberton receives research support from the United Kingdom’s National Institute of Health Research UCLH/UCL Biomedical Research Centre.